Luc Tanguay
Plus aucun poste en cours
Profil
Luc Tanguay served as the President, CEO & Non-Independent Director of Theratechnologies, Inc. from 2012 to 2020.
Prior to that, he was a Director at Ambrilia Biopharma, Inc. from 2006 to 2010.
He also served as the Chairman of Valeo Management LP.
Tanguay received his undergraduate and graduate degrees from the University of Sherbrooke.
Anciens postes connus de Luc Tanguay
| Sociétés | Poste | Fin |
|---|---|---|
| THERATECHNOLOGIES INC. | Directeur Général | 06/04/2020 |
Ambrilia Biopharma, Inc.
 Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Directeur/Membre du Conseil | 31/03/2010 |
Valeo Management LP
 Valeo Management LP Miscellaneous Commercial ServicesCommercial Services Valeo Management LP offers research commercialization services. The firm provides Life sciences and biotechnologies, engineering, information and communications technologies services. The company was founded in 2000 and is headquartered in Montreal, Canada. | Président | - |
Formation de Luc Tanguay
| University of Sherbrooke | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| THERATECHNOLOGIES INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Ambrilia Biopharma, Inc.
Ambrilia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Ambrilia Biopharma, Inc. discovers and develops novel treatments for viral diseases and cancer. Its product portfolio is comprised of oncology and antiviral assets, including two new formulations of existing peptides for cancer treatment, a targeted delivery technology for cancer, an HIV protease inhibitor program as well as HIV integrase and entry inhibitors, Hepatitis C virus inhibitors and anti-Influenza A compounds. The company was founded on November 27, 1986 and is headquartered in Montréal, Canada. | Health Technology |
Valeo Management LP
Valeo Management LP Miscellaneous Commercial ServicesCommercial Services Valeo Management LP offers research commercialization services. The firm provides Life sciences and biotechnologies, engineering, information and communications technologies services. The company was founded in 2000 and is headquartered in Montreal, Canada. | Commercial Services |